Microblink Unveils First-of-Its-Kind Card-Not-Present Fraud Solution with BlinkCard Integration into Microblink Platform at Money 20/20 Europe
This bold expansion cements Microblink's position at the forefront of digital security, arming businesses with an all-in-one, fully automated solution to combat identity and payment fraud in even the most high-risk digital environments.
"This is a game-changer," said Hartley Thompson, President and COO at Microblink. "With BlinkCard now embedded directly into the Microblink Platform, our partners can instantly verify not just who their customers are, but also that their payment card is legitimately present. In a world where Card-Not-Present fraud is skyrocketing, we're delivering a solution no one else has: true, seamless identity and payment verification in a single, scalable platform."
Merchants choose Microblink's payment card scan with liveness detection functionality to safeguard their Card-Not-Present transactions with card-present evidence. The product also powers an alternative authentication method for financial services providers looking to augment their SMS OTP defenses.
The Microblink Platform combines lightning-fast ID capture and global verification with BlinkCard's AI-powered card scanning capabilities, bringing new fraud-fighting muscle to digital payments, card provisioning, and customer authentication. Banks, merchants and payments providers now have access to real-time biometric authentication, document and data validation, and payment fraud checks, all in a frictionless, no-code workflow builder. By combining the capture and screening of credit/debit cards, liveness checks, ID documents and biometrics, Microblink customers can solve use cases, including age verification, CNP fraud reduction and "something you have" authentication.
Key benefits of the integrated solution include:
Card-Not-Present Fraud Protection – Instantly verify payment card presence alongside identity credentials
Frameless, Instant UX – Capture IDs and payment cards in seconds with the industry's fastest, most intuitive UI
AI-Driven Fraud Signals – Uncover fraud at the transaction level with biometric checks, injection attack detection, and proprietary machine learning models
One Platform. Zero Compromises. – Skip complex integrations and reduce third-party dependencies with a cloud-native, automated platform
With this launch, Microblink is redefining what's possible in digital identity—offering an integrated, flexible toolset that reduces fraud, lowers operational overhead, and unlocks better customer experiences.
"We're not just solving identity, we're solving trust," Thompson added. "When you can link a real person to a real payment method, in real-time, you build a foundation of security and confidence that moves businesses forward."
About Microblink
Microblink builds proprietary AI solutions for identity verification and payment fraud, empowering businesses worldwide to improve customers' digital experiences. With more than 12 billion documents processed from over 180 countries, the flagship Microblink Platform is used across industries to onboard more real customers, optimize KYC/AML workflows, and minimize fraud, enabling organizations to make online interactions safer and easier. More at Microblink.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603408802/en/
Contacts
Media Contact: Paul WilkeUpright Position Communications on behalf of Microblinkpaul@uprightcomms.com +1-415-881-7995
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Business Wire
a day ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
a day ago
- Yahoo
Eurobank Ergasias Services And Holdings SA (EGFEF) Q2 2025 Earnings Call Highlights: Strong ...
Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Eurobank Ergasias Services And Holdings SA (EGFEF) reported a robust financial performance in the first half of 2025, achieving an adjusted net profit of 711 million and a return on tangible book value of 16.6%. Net interest income rose 12% year on year, with a strong performance in corporate provision income, which was up by 7% year on year to over 1 billion. Asset quality remained resilient, with the non-performing exposure (NPE) ratio decreasing to 2.8% and coverage exceeding 90%. Loan growth continued strongly with a quarterly net increase of 1 billion, leading to an upward revision of the full-year loan growth target from 3.5 billion to 4 billion. The total capital ratio was enhanced to almost 20% following the issuance of additional tier 1 (AT1) capital, supporting the bank's strong capital position. Negative Points The decline in net interest income is expected to continue due to the trajectory of interest rates, with a lower NII figure anticipated in the second half of the year. Operating costs increased by 6% on a like-for-like basis, with expenses in Greece rising by 6.7% due to higher IT CapEx and staff remuneration. The cost to income ratio in Bulgaria, despite improvements, still reflects the challenges of a declining interest rate environment. The consolidation of CNP in Cyprus resulted in a 20 basis points impact on capital, indicating potential challenges in managing capital deployment. The bank's exposure to CHF loans remains a concern, although it has been addressed through countercyclical provisioning policies. Q & A Highlights Warning! GuruFocus has detected 6 Warning Sign with EGFEF. Q: How do you foresee the trajectory of Net Interest Income (NII) given the recent loan growth and rate cuts? A: Unidentified_3: We reaffirm our initial target of 2.5 billion NII, assuming the ECB terminal rate reaches 1.5%. The expected average DFR for the year is 35 basis points lower than initially expected. The third quarter NII will be lower than the second due to lower base rates, but we maintain our 2.5 billion NII guidance due to higher loan deposits and bond volumes. Q: What are your plans for capital deployment, especially after the CNP acquisition and 81 issuance? A: Unidentified_2: We are interested in non-organic growth in banking, insurance, and asset management in Greece, Bulgaria, and Cyprus. While there are no advanced discussions currently, we aim to keep excess capital for potential inorganic growth opportunities. We are committed to a payout ratio of at least 50%, which may be higher due to strong loan growth and capital reserves. Q: Can you provide guidance on the NII impact from Bulgaria's reserve requirements dropping with EUR accession? A: Unidentified_2: We expect about 1 billion of liquidity to be released, boosting NII from 2026 onwards. The EUR adoption will positively impact the economy and banking sector, with potential for further consolidation. Q: What are the risks to maintaining the current Return on Tangible Equity (ROTE) in the second half of the year? A: Unidentified_3: We expect a lower NII due to interest rate trajectories, with a potential 50 basis points decrease. However, we anticipate exceeding the 15% ROTE target, with no significant variations expected in the second half. Q: How does the potential ECB rate cut impact your NII guidance? A: Unidentified_3: If rates remain at 2%, we expect a positive NII impact of 10-11 million. Our guidance assumes a rate cut in October and December, but if rates stay unchanged, there could be an upside to our NII guidance. Q: Can you clarify the impact of CHF loans on your cost of risk guidance? A: Unidentified_2: We have increased provision overlays across all loan segments, including CHF loans. We do not expect changes to the 60 basis points cost of risk guidance for 2025. Q: What are the main changes in your guidance following the recent results? A: Unidentified_2: We updated our loan growth target from 3.5 billion to 4 billion for 2025. We see upside potential in fee income and expect a return on tangible book value higher than the initial 15% target. Q: How should we think about NII growth into 2026? A: Unidentified_3: We will revisit this when preparing our budget at the end of the year. Current drivers include loan and deposit volumes and sensitivity to interest rates. A detailed business plan for 2026 will be provided in March 2026. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
